Lates News

According to Jieming AI Flash News, TF Securities issued a research report on June 15th, giving a buy rating to Shufun Pharmaceutical Co., Ltd. (300204.SZ). The rating reasons mainly include: 1) Shufun Pharmaceutical: has been deeply cultivating the field of therapeutic drugs for more than twenty years, with rich research and sales pipelines; 2) STSP-0601: Breakthrough therapy designation for new hemophilia drug in development, has submitted a conditional marketing application; 3) STSA-1002: Shows effectiveness in reducing 28-day all-cause mortality rates in ARDS indications; 4) The research pipeline layout is deep, with multiple products in clinical trials rapidly advancing. (Daily Economic News)